Systems-based identification of the Hippo pathway for promoting fibrotic mesenchymal differentiation in systemic sclerosis
dc.contributor.author | Ma, F | |
dc.contributor.author | Tsou, PS | |
dc.contributor.author | Gharaee-Kermani, M | |
dc.contributor.author | Plazyo, O | |
dc.contributor.author | Xing, X | |
dc.contributor.author | Kirma, J | |
dc.contributor.author | Wasikowski, R | |
dc.contributor.author | Hile, GA | |
dc.contributor.author | Harms, PW | |
dc.contributor.author | Jiang, Y | |
dc.contributor.author | Xing, E | |
dc.contributor.author | Nakamura, M | |
dc.contributor.author | Ochocki, D | |
dc.contributor.author | Brodie, WD | |
dc.contributor.author | Pillai, S | |
dc.contributor.author | Maverakis, E | |
dc.contributor.author | Pellegrini, M | |
dc.contributor.author | Modlin, RL | |
dc.contributor.author | Varga, J | |
dc.contributor.author | Tsoi, LC | |
dc.contributor.author | Lafyatis, R | |
dc.contributor.author | Kahlenberg, JM | |
dc.contributor.author | Billi, AC | |
dc.contributor.author | Khanna, D | |
dc.contributor.author | Gudjonsson, JE | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2024-02-02T19:16:33Z | |
dc.date.available | 2024-02-02T19:16:33Z | |
dc.date.issued | 2024-12-01 | |
dc.identifier.issn | 2041-1723 | |
dc.identifier.issn | 2041-1723 | |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pubmed/38172207 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/192258 | en |
dc.description.abstract | Systemic sclerosis (SSc) is a devastating autoimmune disease characterized by excessive production and accumulation of extracellular matrix, leading to fibrosis of skin and other internal organs. However, the main cellular participants in SSc skin fibrosis remain incompletely understood. Here using differentiation trajectories at a single cell level, we demonstrate a dual source of extracellular matrix deposition in SSc skin from both myofibroblasts and endothelial-to-mesenchymal-transitioning cells (EndoMT). We further define a central role of Hippo pathway effectors in differentiation and homeostasis of myofibroblast and EndoMT, respectively, and show that myofibroblasts and EndoMTs function as central communication hubs that drive key pro-fibrotic signaling pathways in SSc. Together, our data help characterize myofibroblast differentiation and EndoMT phenotypes in SSc skin, and hint that modulation of the Hippo pathway may contribute in reversing the pro-fibrotic phenotypes in myofibroblasts and EndoMTs. | |
dc.format.medium | Electronic | |
dc.language | eng | |
dc.publisher | Springer Nature | |
dc.relation.haspart | 210 | |
dc.rights | Licence for published version: Creative Commons Attribution 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Humans | |
dc.subject | Hippo Signaling Pathway | |
dc.subject | Fibrosis | |
dc.subject | Scleroderma, Systemic | |
dc.subject | Myofibroblasts | |
dc.subject | Endothelial Cells | |
dc.subject | Skin | |
dc.subject | Fibroblasts | |
dc.title | Systems-based identification of the Hippo pathway for promoting fibrotic mesenchymal differentiation in systemic sclerosis | |
dc.type | Article | |
dc.identifier.pmid | 38172207 | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/192258/2/Systems-based identification of the Hippo pathway for promoting fibrotic mesenchymal differentiation in systemic sclerosis.pdf | |
dc.identifier.doi | 10.1038/s41467-023-44645-6 | |
dc.identifier.doi | https://dx.doi.org/10.7302/22167 | |
dc.identifier.source | Nature Communications | |
dc.description.version | Accepted version | |
dc.date.updated | 2024-02-02T19:16:26Z | |
dc.identifier.orcid | 0000-0002-6260-0787 | |
dc.identifier.orcid | 0000-0002-2177-2427 | |
dc.identifier.orcid | 0000-0002-6859-7590 | |
dc.identifier.orcid | 0000-0003-3544-3023 | |
dc.identifier.orcid | 0000-0002-0802-2883 | |
dc.identifier.orcid | 0000-0001-9358-9368 | |
dc.identifier.orcid | 0000-0002-9905-875X | |
dc.identifier.orcid | 0000-0001-9355-9564 | |
dc.identifier.orcid | 0000-0003-4720-031X | |
dc.identifier.orcid | 0000-0002-9398-5034 | |
dc.identifier.orcid | 0000-0002-4006-8945 | |
dc.identifier.orcid | 0000-0001-7115-9113 | |
dc.identifier.orcid | 0000-0003-1412-4453 | |
dc.identifier.orcid | 0000-0002-0080-0812 | |
dc.identifier.volume | 15 | |
dc.identifier.issue | 1 | |
dc.identifier.startpage | 210 | |
dc.identifier.name-orcid | Ma, F; 0000-0002-6260-0787 | |
dc.identifier.name-orcid | Tsou, PS | |
dc.identifier.name-orcid | Gharaee-Kermani, M; 0000-0002-2177-2427 | |
dc.identifier.name-orcid | Plazyo, O; 0000-0002-6859-7590 | |
dc.identifier.name-orcid | Xing, X | |
dc.identifier.name-orcid | Kirma, J | |
dc.identifier.name-orcid | Wasikowski, R; 0000-0003-3544-3023 | |
dc.identifier.name-orcid | Hile, GA | |
dc.identifier.name-orcid | Harms, PW; 0000-0002-0802-2883 | |
dc.identifier.name-orcid | Jiang, Y | |
dc.identifier.name-orcid | Xing, E; 0000-0001-9358-9368 | |
dc.identifier.name-orcid | Nakamura, M | |
dc.identifier.name-orcid | Ochocki, D | |
dc.identifier.name-orcid | Brodie, WD | |
dc.identifier.name-orcid | Pillai, S; 0000-0002-9905-875X | |
dc.identifier.name-orcid | Maverakis, E | |
dc.identifier.name-orcid | Pellegrini, M; 0000-0001-9355-9564 | |
dc.identifier.name-orcid | Modlin, RL; 0000-0003-4720-031X | |
dc.identifier.name-orcid | Varga, J | |
dc.identifier.name-orcid | Tsoi, LC | |
dc.identifier.name-orcid | Lafyatis, R; 0000-0002-9398-5034 | |
dc.identifier.name-orcid | Kahlenberg, JM; 0000-0002-4006-8945 | |
dc.identifier.name-orcid | Billi, AC; 0000-0001-7115-9113 | |
dc.identifier.name-orcid | Khanna, D; 0000-0003-1412-4453 | |
dc.identifier.name-orcid | Gudjonsson, JE; 0000-0002-0080-0812 | |
dc.working.doi | 10.7302/22167 | en |
dc.owningcollname | Internal Medicine, Department of |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.